Response of pediatric uveitis to tumor necrosis factor-α inhibitors

Journal of Rheumatology

Volumn 40, Issue 8, 2013, Pages 1394-1403

  Lerman, Melissa A ^a   Burnham, Jon M ^b   Chang, Peter Y ^c   Daniel, Ebenezer ^b   Stephen Foster, C ^d   Hennessy, Sean ^b   Jabs, Douglas A ^e   Joffe, Marshall M ^b   Oktay Kacmaz, R ^f   Levy Clarke, Grace A ^g   Mills, Monte D ^b   Nussenblatt, Robert B ^h   Rosenbaum, James T ⁱ   Suhler, Eric B ⁱ   Thorne, Jennifer E ^j   Kempen, John H ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NEW YORK EYE AND EAR INFIRMARY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f ALLERGAN INC   (United States)

^g JOHNSON AND JOHNSON   (United States)

^h NEI   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

Juvenile idiopathic arthritis; Tumor necrosis factor antagonist; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MEGADOSE; DRUG WITHDRAWAL; EYE EXAMINATION; FEMALE; HUMAN; INCIDENCE; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT;

JUVENILE IDIOPATHIC ARTHRITIS; TUMOR NECROSIS FACTOR ANTAGONIST; UVEITIS;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMORBIDITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; KAPLAN-MEIER ESTIMATE; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; UVEITIS, ANTERIOR;

EID: 84881402866     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121180     Document Type: Article

References (50)

1. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis study. Ophthalmology 2004;111:491-500.
2. BenEzra D, Cohen E, Maftzir G. Uveitis in children and adolescents. Br J Ophthalmol 2005;89:444-8.
3. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol 2003;135:676-80.
4. Holland GN, Denove CS, Yu F. Chronic anterior uveitis in children: Clinical characteristics and complications. Am J Ophthalmol 2009;147:667-78.
5. Kump LI, Cervantes-Castaneda RA, Androudi SN, Foster CS. Analysis of pediatric uveitis cases at a tertiary referral center. Ophthalmology 2005;112:1287-92.
6. Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, et al. Epidemiology and course of disease in childhood uveitis. Ophthalmology 2009;116:1544-51.
7. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk factors for development of uveitis differ between girls and boys with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1824-8.
8. Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol 2003;14:395.
9. Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K. German Uveitis in Childhood Study Group. Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: Suggested modification of the current screening guidelines. Rheumatology 2007;46:1015-9.
10. Kump LI, Castaneda RA, Androudi SN, Reed GF, Foster CS. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis. Ophthalmology 2006;113:1874-7.
11. Saurenmann RK, Levin AV, Feldman BM, Rose JB, Laxer RM, Schneider R, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: A long-term followup study. Arthritis Rheum 2007;56:647-57.
12. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel. Am J Ophthalmol 2000;130:492-513.
13. Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol 2007;143:840-6.
14. Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: Retrospective case series with long-term follow-up. Am J Ophthalmol 2007;144:844-9.
15. Gallagher M, Quinones K, Cervantes-Castaneda RA, Yilmaz T, Foster CS. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthlamol 2007;91:1341.
16. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006;113:860-4.
17. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006;113:308-14.
18. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001;44:1411-5.
19. Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNF-alpha agents. J Pediatr 2006;149:833-6.
20. Sharma SM, Ramanan AV, Riley P, Dick AD. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: Efficacy in joint and ocular disease. Ann Rheum Dis 2007;66:840-1.
21. Simonini G, Zannin ME, Caputo R, Falcini F, de Martino M, Zulian F, et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology 2008;47:1510-4.
22. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125:895.
23. Tugal-Tutkun I, Ayranci O, Kasapcopur O, Kir N. Retrospective analysis of children with uveitis treated with infliximab. J AAPOS 2008;12:611-3.
24. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr 2006;149:572-5.
25. Heinz C, Mingels A, Goebel C, Fuchsluger T, Heiligenhaus A. Chronic uveitis in children with and without juvenile idiopathic arthritis: Differences in patient characteristics and clinical course. J Rheumatol 2008;35:1403-7.
26. Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology 2010;117:1436-41.
27. Kempen JH, Daniel E, Gangaputra S, Dreger K, Jabs DA, Kacmaz RO, et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: The Systemic Immunosuppressive Therapy for Eye Diseases (SITE) cohort study. Ophthalmic Epidemiol 2008;15:47-55.
28. Kempen JH, Daniel E, Dunn JP, Foster CS, Gangaputra S, Hanish A, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: Retrospective cohort study. BMJ 2009;339:b2480.
29. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2.
30. Cassidy J, Kivlin J, Lindsley C, Nocton J, Section on Rheumatology, Section on Ophthalmology. Ophthalmologic examinations in children with juvenile rheumatoid arthritis. Pediatrics 2006;117:1843-5.
31. Daniel E, Thorne JE, Newcomb CW, Pujari SS, Kacmaz RO, Levy-Clarke GA, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149:423-32.e1-2.
32. Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009;116:2188-98.e1.
33. Kacmaz RO, Kempen JH, Newcomb C, Daniel E, Gangaputra S, Nussenblatt RB, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010;117:576-84.
34. Pasadhika S, Kempen JH, Newcomb CW, Liesegang TL, Pujari SS, Rosenbaum JT, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009;148:500-9.e2.
35. Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010;117:356-65.
36. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005;140:509-16.
37. Kempen JH, Ganesh SK, Sangwan VS, Rathinam SR. Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am J Ophthalmol 2008;146:813-8.e1.
38. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978;34:541-54.
39. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: Analysis of a case series of 160 patients. Ophthalmology 2001;108:1134-9.
40. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 2001;45:252-7.
41. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005;53:18-23.
42. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437-40.
43. Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 2006;45:982-9.
44. Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian registry. J Rheumatol 2013;40:74-9.
45. Doycheva D, Deuter C, Stuebiger N, Biester S, Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007;91:180-4.
46. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 1998;82:737.
47. Weiss AW, Wallace CW, Sherry DS. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998;133:266-8.
48. Goebel JC, Roesel M, Heinz C, Michels H, Ganser G, Heiligenhaus A. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol 2011;95:209-13.
49. Tynjala P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology 2008;47:339-44.
50. Caspi RR. A look at autoimmunity and inflammation in the eye. J Clin Invest 2010;120:3073-83.